Welcome, Guest. Please login or register.
February 24, 2024, 08:55:40 pm

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55120
  • Total Topics: 4850
  • Online Today: 130
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 51
Total: 51

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Compared With Harvoni, Viekira Pak May Raise Advanced Liver Disease Risk  (Read 5625 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Those treated for hepatitis C virus (HCV) with Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) may have a greater risk of progression to decompensated cirrhosis in the three months following treatment than those who receive Harvoni (ledipasvir/sofosbuvir).
 
Publishing their findings in Alimentary Pharmacology & Therapeutics, researchers followed participants of the ERCHIVES study for up to 12 weeks after they completed treatment for hep C. The study included 3,728 people who took Viekira Pak, 1,578 people who took Sovaldi (sofosbuvir) plus Olysio (simeprevir) and 440 people who took Harvoni.

Read more...
https://www.hepmag.com/article/compared-harvoni-viekira-pak-may-raise-advanced-liver-disease-risk

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.